Please check your internet connection and try again.
# Lennox-Gastaut Syndrome (LGS) Management
## Overview
LGS is a severe childhood-onset epilepsy syndrome characterized by multiple seizure types (notably tonic and atonic), slow spike-wave complexes on EEG, and cognitive impairment. Management is palliative, requiring multi-drug regimens.
## Primary Indications
Adjunctive treatment of seizures associated with LGS. Common agents approved via FDA include Valproate, Lamotrigine, Topiramate, Rufinamide, Clobazam, Cannabidiol (CBD), and Fenfluramine.
## Adult Dosing
* **Rufinamide:** Start 400–800 mg/day divided BID; titrate by 400–800 mg every 2 days to max 3200 mg/day.
* **Clobazam:** 10–20 mg/day divided BID; titrate based on weight (max 40 mg/day).
* **Cannabidiol:** 2.5 mg/kg BID (5 mg/kg/day); after 1 week, increase to 10 mg/kg/day.
* **Fenfluramine:** Start 0.1 mg/kg BID; target 0.2 mg/kg BID (max 17 mg BID).
## Pediatric Dosing
* **Rufinamide:** Start 10 mg/kg/day divided BID; increase by 10 mg/kg/day every 2 days to max 45 mg/kg/day or 3200 mg/day.
* **Clobazam:** Patients >30 kg: 5 mg/day, titrate to 20 mg/day. Patients ≤30 kg: 5 mg/day, titrate to 10 mg/day.
* **Cannabidiol:** Start 2.5 mg/kg BID (5 mg/kg/day); increase to 10 mg/kg/day after 1 week. Max 20 mg/kg/day.
* **Fenfluramine:** Starting 0.1 mg/kg BID; target 0.2 mg/kg BID (max 17 mg BID).
* **Topiramate:** 5–9 mg/kg/day divided BID.
## Dose Adjustments
* **Renal/Hepatic:** Most AEDs require significant dose reductions in hepatic impairment. Valproate is contraindicated in mitochondrial disorders (POLG mutations).
* **Drug-Drug:** Clobazam and Valproate often require dose reductions when co-administered due to N-CLB metabolite accumulation.
## Contraindications
* **Rufinamide:** Familial Short QT syndrome.
* **Fenfluramine:** History of valvular heart disease or pulmonary arterial hypertension; concurrent use with MAOIs.
* **Valproate:** Known urea cycle disorders; hepatic disease.
## Adverse Effects
* **Common:** Somnolence, fatigue, dizziness, irritability, ataxia.
* **Serious:** DRESS syndrome (Lamotrigine, Rufinamide), suicidal ideation, hepatotoxicity (Valproate, Cannabidiol), nephrolithiasis (Topiramate), cardiac valvulopathy (Fenfluramine).
## Key Drug Interactions
* **Enzyme Inducers (e.g., Carbamazepine, Phenytoin):** Significantly decrease levels of Clobazam, Cannabidiol, and Rufinamide.
* **Valproate:** Increases serum levels of many concurrent AEDs (e.g., Lamotrigine, Clobazam) via enzyme inhibition.
## Monitoring
* **Valproate:** LFTs, CBC (platelets), and serum concentrations.
* **Cannabidiol:** Baseline and periodic LFTs.
* **Fenfluramine:** Echocardiogram at baseline and every 6 months during treatment.
* **General:** Seizure frequency logs, mental health status, and signs of hypersensitivity reactions.
## Clinical Pearls
* **Tapering:** Never discontinue AEDs abruptly due to risk of status epilepticus.
* **Refractory Nature:** LGS is notoriously treatment-resistant. Patients are frequently on three or more concurrent AEDs.
* **Dietary:** Ketogenic diet is a standard non-pharmacological adjunctive therapy for refractory LGS.
* **Dosing Variation:** Always reference institutional protocols, as specific titration schedules vary significantly by provider preference and patient tolerance.
***
**Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and drug information change frequently. Always consult the most current prescribing information (package insert), primary literature, and institutional protocols before making therapeutic decisions.
